Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Genzyme Tissue Repair (GZTR)

No earlier versions found for this Subject.

Return to Genzyme Tissue Repair (GZTR)

I have long liked this subsidiary of Genzyme and lately it has
been under fire for its knee cartillage repair process. The stock is
down from 28 3/4 to under 10. I believe it is time for those with
more nerve than brains -G- to jump in and buy the shares in the
single digits. Not only is the knee product in decent, if
controversial shape, but the real boom will be in products still in
development. Also, with Genzyme behind genzl, they do not have to
worry excessively about burn rate. Any comments will be appreciated
and hopefully we will start a profitable adventure on this one.

Good luck,

Mike Burke